e10vq
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2008
or
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 0-23837
SurModics, Inc.
(Exact name of registrant as specified in its Charter)
|
|
|
MINNESOTA
(State of incorporation)
|
|
41-1356149
(I.R.S. Employer Identification No.) |
9924 West 74th Street
Eden Prairie, Minnesota 55344
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (952) 829-2700
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer þ | Non-accelerated filer o (Do not check if a smaller reporting company) | Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule
12b-2).
Yes o No þ
The number of shares of the registrants common stock, $.05 par value per share, outstanding as of
April 30, 2008 was 18,279,553.
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
SurModics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
September 30, |
|
(In thousands, except share data) |
|
2008 |
|
|
2007 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
26,746 |
|
|
$ |
13,812 |
|
Short-term investments |
|
|
11,083 |
|
|
|
12,496 |
|
Accounts receivable, net of allowance for doubtful
accounts of $40 as of March 31, 2008 and September
30, 2007 |
|
|
17,821 |
|
|
|
16,138 |
|
Inventories |
|
|
2,591 |
|
|
|
2,497 |
|
Deferred tax asset |
|
|
1,116 |
|
|
|
1,116 |
|
Income taxes receivable |
|
|
3,814 |
|
|
|
|
|
Prepaids and other |
|
|
1,424 |
|
|
|
1,836 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
64,595 |
|
|
|
47,895 |
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
20,934 |
|
|
|
19,738 |
|
Restricted cash |
|
|
1,630 |
|
|
|
|
|
Long-term investments |
|
|
43,089 |
|
|
|
43,917 |
|
Deferred tax asset |
|
|
8,597 |
|
|
|
5,908 |
|
Intangible assets , net |
|
|
16,983 |
|
|
|
18,399 |
|
Goodwill |
|
|
18,298 |
|
|
|
15,686 |
|
Other assets |
|
|
10,911 |
|
|
|
19,788 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
185,037 |
|
|
$ |
171,331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
4,216 |
|
|
$ |
2,541 |
|
Accrued liabilities |
|
|
3,394 |
|
|
|
4,187 |
|
Accrued income taxes payable |
|
|
|
|
|
|
6,227 |
|
Deferred revenue |
|
|
3,911 |
|
|
|
5,586 |
|
Other current liabilities |
|
|
4,451 |
|
|
|
1,311 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
15,972 |
|
|
|
19,852 |
|
Deferred revenue, less current portion |
|
|
24,203 |
|
|
|
20,305 |
|
Other long-term liabilities |
|
|
1,597 |
|
|
|
252 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
41,772 |
|
|
|
40,409 |
|
|
|
|
|
|
|
|
Stockholders Equity |
|
|
|
|
|
|
|
|
Series A preferred stock $.05 par value, 450,000
shares authorized; no shares issued and
outstanding |
|
|
|
|
|
|
|
|
Common stock $.05 par value, 45,000,000 shares
authorized; 18,233,618 and 18,164,980 shares
issued and outstanding |
|
|
912 |
|
|
|
909 |
|
Additional paid-in capital |
|
|
79,863 |
|
|
|
76,670 |
|
Accumulated other comprehensive income |
|
|
37 |
|
|
|
1,723 |
|
Retained earnings |
|
|
62,453 |
|
|
|
51,620 |
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
143,265 |
|
|
|
130,922 |
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
185,037 |
|
|
$ |
171,331 |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial
statements.
2
SurModics, Inc. and Subsidiaries
Condensed Consolidated Statements of Income
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|
|
March 31, |
|
|
March 31, |
|
(In thousands, except per share data) |
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties and license fees |
|
$ |
13,809 |
|
|
$ |
13,028 |
|
|
$ |
26,987 |
|
|
$ |
26,247 |
|
Product sales |
|
|
4,700 |
|
|
|
3,381 |
|
|
|
9,907 |
|
|
|
6,107 |
|
Research and development |
|
|
7,198 |
|
|
|
953 |
|
|
|
12,642 |
|
|
|
1,748 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
25,707 |
|
|
|
17,362 |
|
|
|
49,536 |
|
|
|
34,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product costs |
|
|
2,154 |
|
|
|
1,092 |
|
|
|
4,129 |
|
|
|
2,179 |
|
Research and development |
|
|
10,370 |
|
|
|
5,717 |
|
|
|
19,904 |
|
|
|
10,924 |
|
Selling, general and administrative |
|
|
6,002 |
|
|
|
2,468 |
|
|
|
10,751 |
|
|
|
4,805 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating costs and expenses |
|
|
18,526 |
|
|
|
9,277 |
|
|
|
34,784 |
|
|
|
17,908 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
|
7,181 |
|
|
|
8,085 |
|
|
|
14,752 |
|
|
|
16,194 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment income |
|
|
1,051 |
|
|
|
1,187 |
|
|
|
2,004 |
|
|
|
2,520 |
|
Other income (loss) |
|
|
133 |
|
|
|
(15 |
) |
|
|
900 |
|
|
|
(19 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income |
|
|
1,184 |
|
|
|
1,172 |
|
|
|
2,904 |
|
|
|
2,501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
|
8,365 |
|
|
|
9,257 |
|
|
|
17,656 |
|
|
|
18,695 |
|
Income tax provision |
|
|
(3,258 |
) |
|
|
(3,582 |
) |
|
|
(6,903 |
) |
|
|
(7,029 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
5,107 |
|
|
$ |
5,675 |
|
|
$ |
10,753 |
|
|
$ |
11,666 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income per share |
|
$ |
0.28 |
|
|
$ |
0.31 |
|
|
$ |
0.60 |
|
|
$ |
0.64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per share |
|
$ |
0.28 |
|
|
$ |
0.31 |
|
|
$ |
0.58 |
|
|
$ |
0.64 |
|
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
18,102 |
|
|
|
18,017 |
|
|
|
18,055 |
|
|
|
18,232 |
|
Dilutive effect of outstanding stock options |
|
|
326 |
|
|
|
116 |
|
|
|
366 |
|
|
|
110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
18,428 |
|
|
|
18,133 |
|
|
|
18,421 |
|
|
|
18,342 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
SurModics, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
March 31, |
|
(In thousands) |
|
2008 |
|
|
2007 |
|
Operating Activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
10,753 |
|
|
$ |
11,666 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
2,993 |
|
|
|
1,960 |
|
(Gain) loss on equity method investment and sales of investments |
|
|
(857 |
) |
|
|
19 |
|
Amortization of premium (discount) on investments |
|
|
2 |
|
|
|
(993 |
) |
Stock-based compensation |
|
|
5,351 |
|
|
|
2,870 |
|
Deferred taxes |
|
|
(1,129 |
) |
|
|
(102 |
) |
Excess tax benefits from exercise of stock options |
|
|
(765 |
) |
|
|
|
|
Loss on disposals of property and equipment |
|
|
22 |
|
|
|
7 |
|
Change in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(1,683 |
) |
|
|
4,613 |
|
Inventories |
|
|
(94 |
) |
|
|
(38 |
) |
Accounts payable and accrued liabilities |
|
|
31 |
|
|
|
(1,102 |
) |
Income taxes |
|
|
(7,603 |
) |
|
|
(2,349 |
) |
Deferred revenue |
|
|
1,988 |
|
|
|
375 |
|
Prepaids and other |
|
|
(65 |
) |
|
|
(472 |
) |
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
8,944 |
|
|
|
16,454 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing Activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(2,056 |
) |
|
|
(1,610 |
) |
Proceeds from sales of property and equipment |
|
|
26 |
|
|
|
|
|
Purchases of available-for-sale investments |
|
|
(7,810 |
) |
|
|
(63,211 |
) |
Sales/maturities of available-for-sale investments |
|
|
16,215 |
|
|
|
85,707 |
|
Purchases of held-to-maturity investments |
|
|
(4,333 |
) |
|
|
|
|
Purchase of licenses and patents |
|
|
(65 |
) |
|
|
(68 |
) |
Investment in other strategic assets |
|
|
|
|
|
|
(2,117 |
) |
Collection of notes receivable |
|
|
5,870 |
|
|
|
261 |
|
Cash restricted for land purchase |
|
|
(1,630 |
) |
|
|
|
|
Other investing activities |
|
|
(567 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by investing activities |
|
|
5,650 |
|
|
|
18,962 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities: |
|
|
|
|
|
|
|
|
Excess tax benefits from exercise of stock options |
|
|
765 |
|
|
|
|
|
Issuance of common stock |
|
|
1,848 |
|
|
|
1,885 |
|
Repurchase of common stock |
|
|
(2,601 |
) |
|
|
(35,030 |
) |
Purchase of common stock to fund employee taxes |
|
|
(1,450 |
) |
|
|
|
|
Repayment of notes payable |
|
|
(222 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(1,660) |
) |
|
|
(33,145 |
) |
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
12,934 |
|
|
|
2,271 |
|
Cash and cash equivalents |
|
|
|
|
|
|
|
|
Beginning of period |
|
|
13,812 |
|
|
|
3,751 |
|
|
|
|
|
|
|
|
End of period |
|
$ |
26,746 |
|
|
$ |
6,022 |
|
|
|
|
|
|
|
|
|
Supplemental
Information |
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
$ |
15,381 |
|
|
$ |
9,468 |
|
Noncash transaction accrued earnout payments in connection with business
acquisition agreements |
|
$ |
3,148 |
|
|
$ |
|
|
Noncash transaction acquisition of property, plant, and equipment on account |
|
$ |
953 |
|
|
$ |
118 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
SurModics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Period Ended March 31, 2008
(Unaudited)
(1) Basis of Presentation
The accompanying unaudited interim condensed consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the United States of
America and reflect all adjustments, consisting solely of normal recurring adjustments, needed to
fairly present the financial results for the periods presented. These financial statements include
some amounts that are based on managements best estimates and judgments. These estimates may be
adjusted as more information becomes available, and any adjustment could be significant. The impact
of any change in estimates is included in the determination of earnings in the period in which the
change in estimate is identified. The results of operations for the three-month and six-month
periods ended March 31, 2008 are not necessarily indicative of the results that may be expected for
the entire 2008 fiscal year.
The
six-month period ended March 31, 2008 includes a reclassification of
$807,000 of research and development expenses reported as product
costs in the first quarter. The expenses reclassified were
out-of-pocket project costs related to research and development
activities.
In July 2007, the Company acquired Brookwood Pharmaceuticals, Inc., from Southern Research
Institute, for $40 million in cash at closing and up to an additional $22 million in cash upon the
successful achievement of specified milestones. In the second quarter of fiscal 2008 a milestone
was achieved and $2 million of additional purchase price was recorded as an increase to goodwill.
Brookwood specializes in proprietary injectable microparticles and implants to provide sustained
delivery of drugs being developed by leading pharmaceutical, biotechnology and medical device
clients as well as emerging companies. This acquisition is helping the Company broaden its
technology offerings to customers, diversifying the range of markets in which the Company
participates, expanding the Companys customer base, and enhancing the pipeline of potential
revenue generating opportunities.
In August 2007, the Company acquired BioFX Laboratories, Inc., a provider of substrates to the
in vitro diagnostics industry, for $11.3 million in cash at closing and up to an additional $11.4
million in cash upon the successful achievement of specified revenue targets. In the first quarter
of fiscal 2008 a milestone was achieved and $1.1 million of additional purchase price was recorded
as an increase to goodwill. BioFX is a leading manufacturer of substrates, a critical component of
diagnostic test kits used to detect and signal that a certain reaction has taken place. The
acquisition of BioFX is broadening the Companys product portfolio in the in vitro diagnostics
market.
The operating results for the Brookwood Pharmaceuticals, Inc. and BioFX Laboratories, Inc.
businesses are included in the consolidated results of operations from the dates of acquisition.
In accordance with the rules and regulations of the United States Securities and Exchange
Commission, the Company has omitted footnote disclosures that would substantially duplicate the
disclosures contained in the audited consolidated financial statements of the Company. These
unaudited condensed consolidated financial statements should be read
together with the audited consolidated financial statements for the year ended September 30, 2007, and footnotes thereto included in the
Companys Form 10-K as filed with the United States Securities and Exchange Commission on December
14, 2007.
(2) New Accounting Pronouncements
In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of
Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements (SFAS No. 157). This
statement establishes a framework for measuring fair value and requires enhanced disclosures about
fair value measurements. SFAS No. 157 applies to fair value measurements required by existing
accounting pronouncements and does not require any new fair value measurements. SFAS No. 157 is
effective for the Company in fiscal 2009. FASB Staff Position No. FAS 157-2 provides a deferral of
SFAS No. 157 provisions for non-financial assets and liabilities until fiscal 2010. The Company has
not determined the impact, if any, the adoption of this statement will have on its consolidated
financial statements.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities (SFAS No. 159). SFAS No. 159 permits entities to choose to measure many
financial assets and financial liabilities at fair value. Unrealized gains and losses on items for
which the fair value option has been elected will be reported in earnings. SFAS No. 159 is
effective for the Company in fiscal 2009. The Company is currently evaluating the impact of SFAS
No. 159 on its consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations (SFAS No. 141(R)),
which establishes principles and requirements for how an acquirer recognizes and measures in its
financial statements the identifiable assets acquired, the liabilities assumed, and any
noncontrolling interest in an acquiree, including the recognition and measurement of goodwill
acquired in a business combination. SFAS No. 141(R) is effective for the Company in
fiscal 2010. Earlier adoption is prohibited and once adopted SFAS No. 141(R) will impact
recognition and measurement of future business combinations.
5
(3) Inventories
Inventories are principally stated at the lower of cost or market using the specific
identification method and include direct labor, materials and overhead. Inventories consisted of
the following components (in thousands) :
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
September 30, |
|
|
|
2008 |
|
|
2007 |
|
Raw materials |
|
$ |
1,129 |
|
|
$ |
1,241 |
|
Finished products |
|
|
1,462 |
|
|
|
1,256 |
|
|
|
|
|
|
|
|
Total |
|
$ |
2,591 |
|
|
$ |
2,497 |
|
|
|
|
|
|
|
|
(4) Restricted Cash
The Company has entered into an agreement to purchase an undeveloped parcel of land, as
described in Note 12. To secure the performance of its obligations under the purchase agreement,
the Company delivered a standby letter of credit in the amount of $1.6 million. This letter of
credit is fully collateralized by restricted cash that the Company deposited with the issuing
institution.
(5) Other Assets
Other assets consist principally of strategic investments. The Company accounts for its
strategic investments under the cost method, except for its investments in Paragon Intellectual
Properties, LLC (Paragon), Paragons subsidiary, Apollo Therapeutics, LLC, and Brookwoods
investment in Aeon Biosience, Inc. (included in the Other category in the table below), which are
accounted for under the equity method. Other assets consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
September 30, |
|
|
|
2008 |
|
|
2007 |
|
Investment in OctoPlus |
|
$ |
5,506 |
|
|
$ |
8,762 |
|
Long-term portion of note receivable |
|
|
|
|
|
|
5,158 |
|
Investment in Paragon and subsidiary |
|
|
3,242 |
|
|
|
3,632 |
|
Investment in ThermopeutiX |
|
|
1,185 |
|
|
|
1,185 |
|
Investment in Novocell |
|
|
559 |
|
|
|
559 |
|
Other |
|
|
419 |
|
|
|
492 |
|
|
|
|
|
|
|
|
Total other assets |
|
$ |
10,911 |
|
|
$ |
19,788 |
|
|
|
|
|
|
|
|
In September 2005, the Company entered into an agreement to sell a contract manufacturing
facility and 27 acres of land located in Bloomington, Minnesota. The terms of the sale agreement
included a $100,000 cash down payment and a note receivable of $6.9 million, which was
collateralized by the property. The terms of the note called for monthly installment payments of
principal and interest at 6% with the remaining amount due and payable in September 2010. On
January 14, 2008, the outstanding balance (including principal and accrued interest) of $5.8
million was repaid in its entirety.
The Company recognized revenue of $1.5 million and $76,000 for the three-month period ended
March 31, 2008 and 2007, respectively, and recognized revenue of $2.4 million and $125,000 for the
six-month period ended March 31, 2008 and 2007, respectively, from activity with
companies in which it had a strategic investment.
(6) Intangible Assets
Intangible assets consist principally of acquired patents and technology, customer
relationships, licenses, and trademarks. The Company recorded amortization expense of $741,000, and
$447,000 for the three months ended March 31, 2008 and 2007, respectively. The Company recorded
amortization expense of $1,481,000, and $532,000 for the six months ended March 31, 2008 and 2007,
respectively.
In September 2004, the Company made a commitment to purchase for $7.0 million certain
additional sublicense rights and the accompanying future royalty revenue streams under certain
sublicenses through an amendment to the Companys diagnostic format patent license with Abbott
Laboratories. Prior to such amendment, the Company was receiving only a
6
portion of the royalties
under such sublicenses. The first $5.0 million installment was paid in fiscal 2005, and an
additional
$1.0 million installment was paid in fiscal 2007. The remaining $1.0 million installment is
reflected in other current liabilities.
Intangible assets consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Useful life |
|
|
March 31, |
|
|
September 30, |
|
|
|
(in years) |
|
|
2008 |
|
|
2007 |
|
Customer list |
|
|
9 11 |
|
|
$ |
7,340 |
|
|
$ |
7,340 |
|
Abbott license |
|
|
4 |
|
|
|
7,037 |
|
|
|
7,037 |
|
Core technology |
|
|
8 18 |
|
|
|
6,930 |
|
|
|
6,933 |
|
Patents and other |
|
|
7 20 |
|
|
|
2,056 |
|
|
|
1,988 |
|
Trademarks |
|
|
|
|
|
|
580 |
|
|
|
580 |
|
Less accumulated amortization of intangible assets |
|
|
|
|
|
|
(6,960 |
) |
|
|
(5,479 |
) |
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
|
|
|
$ |
16,983 |
|
|
$ |
18,399 |
|
|
|
|
|
|
|
|
|
|
|
|
Based on the intangible
assets in service as of March 31, 2008, estimated amortization expense
for each of the next five years ending March 31 is as follows ( in thousands ):
|
|
|
|
|
2009 |
|
|
$2,550 |
|
2010 |
|
|
1,299 |
|
2011 |
|
|
1,299 |
|
2012 |
|
|
1,299 |
|
2013 |
|
|
1,299 |
|
(7) Stock-based Compensation
The Companys stock-based compensation
expenses were as follows (in thousands) :
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
Six months ended |
|
|
|
March 31, |
|
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
Product costs |
|
$ |
63 |
|
|
$ |
25 |
|
|
$ |
87 |
|
|
$ |
52 |
|
Research and development |
|
|
1,039 |
|
|
|
714 |
|
|
|
1,876 |
|
|
|
1,407 |
|
Selling, general and administrative |
|
|
2,296 |
|
|
|
719 |
|
|
|
3,388 |
|
|
|
1,411 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
3,398 |
|
|
$ |
1,458 |
|
|
$ |
5,351 |
|
|
$ |
2,870 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2008, approximately $15.1 million of total unrecognized compensation costs
related to non-vested awards is expected to be recognized over a weighted average period of
approximately 2.5 years.
Stock Option Plans
The Company accounts for stock-based compensation in accordance with SFAS No. 123(R), Share
Based Payment (SFAS 123(R)), which requires all share-based payments, including grants of stock
options, to be recognized in the income statement as an operating expense, based on their fair
values, over the requisite service period.
7
The Company uses the Black-Scholes option pricing model to determine the weighted average fair
value of options. The weighted average fair values of options granted during the three-month
periods ended March 31, 2008 and 2007 were $22.21 and $14.54, respectively. The weighted average
fair values of options granted during the six-month periods ended March 31, 2008 and 2007 were
$25.19 and $16.56, respectively. The assumptions used as inputs in the model were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
Six months ended |
|
|
March 31, |
|
March 31, |
|
|
2008 |
|
2007 |
|
2008 |
|
2007 |
Risk-free interest rates |
|
|
3.0 |
% |
|
|
4.8 |
% |
|
|
3.6 |
% |
|
|
4.7 |
% |
Expected life (years) |
|
|
6.2 |
|
|
|
4.9 |
|
|
|
6.5 |
|
|
|
5.8 |
|
Expected volatility |
|
|
44.6 |
% |
|
|
42.5 |
% |
|
|
47.8 |
% |
|
|
49.4 |
% |
Dividend yield |
|
|
0 |
% |
|
|
0 |
% |
|
|
0 |
% |
|
|
0 |
% |
The risk-free interest rate assumption was based on yields for U.S. Treasury bonds with maturities
similar to those of the expected term of the award. The expected life of options granted is
determined based on the Companys experience. Expected volatility is based on the Companys stock
price movement over a period approximating the expected term. Based on managements judgment,
dividend rates are expected to be zero for the expected life of the options. The Company also
estimates forfeitures of options granted, which is based on historical experience.
The Companys Incentive Stock Options (ISO) are granted at a price of at least 100% of the
fair market value of the common stock of the Company (Common Stock) on the date of the grant or
110% with respect to optionees who own more than 10% of the total combined voting power of all
classes of stock. ISOs expire in seven years or upon termination of employment and are exercisable
at a rate of 20% per year commencing one year after the date of grant. Nonqualified stock options
(NQSO) are granted at fair market value on the date of grant. NQSOs expire in 7 to 10 years and
are exercisable at rates of 20% per year from the date of grant, or 20% to 33% per year commencing
one year after the date of grant.
Restricted Stock Awards
The Company has entered into restricted stock agreements with certain key employees, covering
the issuance of Common Stock (Restricted Stock). Under SFAS No.123(R), these shares are
considered to be non-vested shares. The Restricted Stock will be released to the key employees if
they are employed by the Company at the end of the vesting period.
The stock-based compensation table
above includes Restricted Stock expenses of $749,000 and $1,206,000 for the three-month and
six-month periods ended March 31, 2008, respectively, and $287,000 and $556,000 for the three-month
and six-month periods ended March 31, 2007, respectively.
Performance Share Awards
Historically, the Company has entered into performance share agreements with certain key
employees, covering the issuance of Common Stock (Performance Shares). The Performance Shares
vest upon the achievement of certain performance objectives, which must be achieved during the
performance period. Compensation is recognized in each period based on managements best estimate
of the achievement level of the grants specified performance objectives and the resulting vesting
amounts. For the three-month and six-month periods ended March 31, 2008, the Company recognized
$308,000 associated with the fair value of vesting of grants. For the three-month and six-month
periods ended March 31, 2007, the Company recognized $380,000 and $138,000 of the fair value of
anticipated vesting of grants, respectively. The stock-based compensation table above includes the
Performance Share expenses.
1999 Employee Stock Purchase Plan
Under the 1999 Employee Stock Purchase Plan (Stock Purchase Plan), the Company is authorized
to issue up to 200,000 shares of common stock. All full-time and part-time employees can choose to
have up to 10% of their annual compensation withheld to purchase the Companys common stock at
purchase prices that are 85% of the average closing price as defined in the Stock Purchase Plan. As
of March 31, 2008 and 2007, there were $57,000 and $48,000 of employee contributions, respectively,
included in accrued liabilities in the accompanying condensed consolidated balance sheets. Stock
compensation expense recognized related to the Stock Purchase Plan for three-month periods ended
March 31, 2008 and 2007 totaled $45,000 and $39,000, respectively. Stock compensation expense
recognized related to the Stock Purchase Plan for the six-month periods ended March 31, 2008 and
2007 totaled $83,000 and $79,000, respectively. The stock-based compensation table above includes the
Stock Purchase Plan expenses.
8
(8) Comprehensive Income
The components of comprehensive income are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
Six months ended |
|
|
|
March 31, |
|
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
Net income |
|
$ |
5,107 |
|
|
$ |
5,675 |
|
|
$ |
10,754 |
|
|
$ |
11,666 |
|
Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized holding
gains (losses) on
available-for-sale
securities arising
during the period, net
of tax |
|
|
(671 |
) |
|
|
1,041 |
|
|
|
(882 |
) |
|
|
2,841 |
|
Adjustment for
realized (gains)
losses included in net
income, net of tax |
|
|
(241 |
) |
|
|
9 |
|
|
|
(804 |
) |
|
|
12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income |
|
$ |
4,195 |
|
|
$ |
6,725 |
|
|
$ |
9,068 |
|
|
$ |
14,519 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9) Income Taxes
The Company adopted the provisions of FASB Interpretation No. 48 (FIN 48) Accounting for
Uncertainty in Income Taxes An Interpretation of FASB Statement No. 109, on October 1, 2007. Upon
adoption of FIN 48, the Company recorded a net $79,000 benefit related to taxes, which was recorded
as an increase to the October 1, 2007 beginning retained earnings balance. As of the adoption date,
the Company has gross unrecognized tax benefits of $1.1 million and if recognized, this total
amount would impact the effective tax rate. The Company has classified $160,000 of the gross
unrecognized tax benefits as a current liability, reflecting the amount the Company expects to pay
during the next twelve months in connection with certain amended tax returns filed by the Company.
The remaining liability for unrecognized tax benefits has been classified as non-current, as no
payments are expected to be made in the next twelve months. The Company does not anticipate any
other significant increases or decreases in unrecognized tax benefits within twelve months of
adoption of FIN 48. Interest and penalties related to unrecognized tax benefits are recorded in
income tax expense. As of October 1, 2007, a gross balance of $445,000 of interest and penalties
has been accrued related to the unrecognized tax benefits balance.
The Company files tax returns, including returns for its subsidiaries, in the United States
federal jurisdiction and in various state jurisdictions. Uncertain tax positions are related to tax
years that remain subject to examination. As of the date of the adoption, U.S. tax returns for
fiscal years ended September 30, 2005, 2006, and 2007 remain subject to examination by federal tax
authorities. Tax returns for state and local jurisdictions for fiscal years ended September 30,
2003 through 2007 remain subject to examination by state and local tax authorities.
(10) Operating Segments
Operating segments are defined as components of an enterprise about which separate financial
information is available that is evaluated regularly by the chief operating decision maker, or
decision making group, in deciding how to allocate resources and in assessing performance.
SurModics manages its business on the basis of the operating segments noted in the table
below, which are comprised of the Companys seven business units. The three operating segments are
aggregated into one reportable segment. The Drug Delivery operating segment contains: (1) the
Drug Delivery business unit, which is responsible for technologies dedicated to site specific
delivery of drugs; (2) the Ophthalmology business unit, which is dedicated to the advancement of
treatments for eye diseases, such as age-related macular degeneration (AMD) and diabetic macular
edema (DME), two of the leading causes of blindness; and (3) the Brookwood Pharmaceuticals unit,
which provides proprietary polymer-based technologies to companies developing improved
pharmaceutical products. The Hydrophilic and Other operating segment consists of three business
units: (1) the Hydrophilic Technologies business unit, which focuses on enhancing medical devices
with advanced lubricious coatings that facilitate their placement and maneuverability in the body;
(2) the Regenerative Technologies business unit, which is developing platforms intended to augment
or replace tissue/organ function (e.g., cell encapsulation applications), or to modify medical
devices to facilitate tissue/organ recovery through natural repair mechanisms (e.g.,
hemo/biocompatible or prohealing coatings); and (3) the Orthopedics business unit, which is
committed to innovative solutions for orthopedics patients using proven SurModics technologies, and
creating new technology solutions to existing patient care gaps in the orthopedics field. The In
Vitro operating segment contains the In Vitro Technologies (formerly Diagnostics and Drug
Discovery) business unit, which includes the Companys genomics slide technologies, stabilization
products, antigens and substrates for immunoassay diagnostics tests, its in vitro diagnostic
format technology and its synthetic ECM cell culture products.
9
Each operating segment has similar economic characteristics, technology, manufacturing
processes, customers, regulatory environments, and shared infrastructures. The Company manages its
expenses on a company-wide basis, as many costs and activities are shared among the business units.
The focus of the business units is providing solutions to customers and maximizing financial
performance over the long term. The accounting policies for segment reporting are the same as for
the Company as a whole. The table below presents revenue from the three operating segments for the
three-month and six-month periods in fiscal 2008 and 2007, respectively (in thousands ):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
Six months ended |
|
|
|
March 31, |
|
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
Operating segment: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Drug Delivery |
|
$ |
11,955 |
|
|
$ |
6,205 |
|
|
$ |
22,723 |
|
|
$ |
12,834 |
|
Hydrophilic and Other |
|
|
8,261 |
|
|
|
6,546 |
|
|
|
15,815 |
|
|
|
11,823 |
|
In Vitro |
|
|
5,491 |
|
|
|
4,611 |
|
|
|
10,998 |
|
|
|
9,445 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
25,707 |
|
|
$ |
17,362 |
|
|
$ |
49,536 |
|
|
$ |
34,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11) Share Repurchases
In November 2007, the companys Board of Directors authorized the repurchase of $35.0 million
of the Companys common stock in open-market transactions, private transactions, tender offers, or
other transactions. The repurchase authorization does not have a fixed expiration date. During the
three months ended March 31, 2008, the Company repurchased 64,200 shares for $2.6 million at an
average price of $40.56 per share under this plan. No shares were purchased in the three months
ended December 31, 2007. As of March 31, 2008, $32.4 million remains authorized and available for
future purchases under the repurchase program.
(12) Commitments and Contingencies
Litigation. From time to time, the Company may become involved in various legal actions
involving its products and technologies, including intellectual property disputes. The outcomes of
these legal actions are not within the Companys complete control and may not be known for
prolonged periods of time. In some actions, the claimants seek damages, as well as other relief,
including injunctions barring the sale of products that are the subject of the lawsuit, which, if
granted, could require significant expenditures or result in lost revenues. In accordance with SFAS
No. 5, Accounting for Contingencies, the Company records a liability in the consolidated
financial statements for these actions when a loss is known or considered probable and the amount
can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and
no amount within the range is a better estimate, the minimum amount of the range is accrued. If a
loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or
range of loss is disclosed. In most cases, significant judgment is required to estimate the amount
and timing of a loss to be recorded. While it is not possible to predict the outcome for most of
the actions discussed below and the Company believes that it has meritorious defenses against these
matters, it is possible that costs associated with them could have a material adverse impact on the
Companys consolidated earnings, financial condition or cash flows.
Land Purchase Commitment. In August 2007, the Company entered into an agreement to purchase an
undeveloped parcel of land in Eden Prairie, Minnesota for approximately $3.6 million (including a
non-refundable deposit of $100,000 paid to the seller at the time the purchase agreement was
signed). The agreement requires that the Company complete the purchase on or before August 24, 2008
(the Closing Date). While it is the Companys current expectation to complete the purchase on or
before the Closing Date, the Company will be required to pay the seller $1.6 million if it fails to
do so and will have no further rights to acquire the land. This $1.6 million commitment is secured
by a standby letter of credit as discussed in Note 4.
(13) Subsequent Events
In April 2008, the Company acquired a 286,000 square foot facility situated on 42 acres
located in Birmingham, Alabama for $12.2 million. The Company plans to remodel the existing
facility to accommodate research and development, clinical manufacturing and commercial
manufacturing of drug delivery products for pharmaceutical and biotechnology customers. Total
investment in this facility, including the $12.2 million already paid, is expected to approximate
$30.0 million, and renovation and remodeling is expected to be completed over the next two years.
In May 2008, the
Company invested an additional $2.5 million in a subsidiary of Paragon (see
Note 5 for additional information on previous investments in
Paragon). The arrangement with the Paragon subsidiary called for the Company to invest the additional amount based upon successful completion of
specified development milestones.
10
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
Overview
SurModics is a leading provider of surface modification and drug delivery technologies to the
healthcare industry. The Company is organized into three operating segments composed of seven
technology-centered and industry-focused business units. The Drug Delivery operating segment
consists of three business units: (1) the Drug Delivery business unit, which is responsible for
technologies dedicated to site-specific delivery of drugs; (2) the Ophthalmology business unit,
which is dedicated to the advancement of treatments for eye diseases, such as age-related macular
degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of blindness; and
(3) the Brookwood Pharmaceuticals business unit, which provides proprietary polymer-based
technologies to companies developing improved pharmaceutical products. The Hydrophilic and Other
operating segment consists of three business units: (1) the Hydrophilic Technologies business unit,
which focuses on enhancing medical devices with advanced lubricious coatings that facilitate their
placement and maneuverability in the body; (2) the Regenerative Technologies business unit, which
is developing platforms intended to augment or replace tissue/organ function (e.g., cell
encapsulation applications), or to modify medical devices to facilitate tissue/organ recovery
through natural repair mechanisms (e.g., hemo/biocompatible or prohealing coatings); and (3) the
Orthopedics business unit, which is committed to innovative solutions for orthopedics patients
using proven SurModics technologies, and creating new technology solutions to existing patient care
gaps in the orthopedics field. The In Vitro operating segment consists of the In Vitro
Technologies (formerly Diagnostics and Drug Discovery) business unit, which includes our genomics
slide technologies, our stabilization products, antigens and substrates for immunoassay diagnostic
tests, our in vitro diagnostic format technology and our synthetic ECM cell culture products.
Revenue in each of our operating segments is derived from three primary sources: (1) royalties
and license fees from licensing our patented surface modification and drug delivery technologies
and in vitro diagnostic formats to customers; the vast majority (typically in excess of 90%) of
revenue in the royalties and license fees category is in the form of royalties; (2) the sale of
reagent chemicals to licensees of our technologies, stabilization products, antigens and substrates
to the diagnostics industry and coated glass slides to the genomics market; and (3) research and
development fees generated on customer projects. Revenue should be expected to fluctuate from
quarter to quarter depending on, among other factors: our customers success in selling products
incorporating our technologies; the timing of introductions of coated products by customers; the
timing of introductions of products that compete with our customers products; the number and
activity level associated with customer development projects; the number and terms of new license
agreements that are finalized; the value of reagent chemicals and other products sold to customers;
and the timing of future acquisitions we complete, if any.
In June 2007, we signed a collaborative research and license agreement with Merck (the Merck
Agreement) to pursue the joint development and commercialization of the I-vation sustained drug
delivery system with triamcinolone acetonide and other products that combine Merck proprietary drug
compounds with the I-vation system for the treatment of serious retinal diseases. Under the terms
of our agreement with Merck, we received an up-front license fee of $20 million and may receive up
to an additional $288 million in fees and development milestones associated with the successful
product development and attainment of appropriate U.S. and EU regulatory approvals for these new
combination products. We will also be paid for our activities in researching and developing these
combination products. Additionally, under the terms of our agreement with Merck, we will be
responsible for the exclusive manufacture and supply of clinical and commercial products. Once
products licensed under the agreement are commercialized, we will also receive royalties on sales
of such products.
Under EITF 00-21, we are amortizing the $20 million license fee we received upon signing the
agreement in June 2007, over the economic life of the technology we licensed to Merck, or 16 years.
This accounting treatment, and the resulting amortization, also applies to current and future
license fees and milestone payments. The commercial R&D fees that we are paid by Merck are also
amortized over the same economic life. However, all of the costs of the R&D work we perform for
Merck are expensed in the period performed. In addition, we recognize billings to Merck for
reimbursed out-of-pocket expenses in the period incurred; accordingly such amounts are not
amortized. As of March 31, 2008, the deferred revenue balance related to the Merck Agreement was
$24.9 million.
In July 2007, we acquired Brookwood Pharmaceuticals, Inc. (Brookwood), from Southern
Research Institute, for $40 million in cash at closing and up to an additional $22 million in cash
upon the successful achievement of specified milestones. In the second quarter of fiscal 2008 a
milestone was achieved and $2 million of additional purchase price was recorded as an increase to
goodwill. Brookwood specializes in proprietary injectable microparticles and implants to provide
sustained delivery of drugs being developed by leading pharmaceutical, biotechnology and medical
device clients as well as emerging companies. This acquisition is expected to help us broaden our
technology offerings to our customers, diversify the range of markets in which we participate,
expand our customer base, and enhance our pipeline of potential revenue generating opportunities.
In August 2007, we acquired BioFX Laboratories, Inc. (BioFX), a provider of substrates to
the in vitro diagnostics industry, for $11.3 million in cash at closing and up to an additional
$11.4 million in cash upon the successful achievement of specified revenue targets. In the first
quarter of fiscal 2008 a milestone was achieved and $1.1 million of additional purchase
11
price was recorded as an increase to goodwill. BioFX is a leading manufacturer of substrates, a
critical component of diagnostic test kits used to detect and signal that a certain reaction has
taken place. We expect our acquisition of BioFX to broaden our product portfolio in the in vitro
diagnostics market.
The operating results for the Brookwood and BioFX businesses are included in the consolidated
results of operations from the dates of acquisition.
For financial accounting and reporting purposes, we treat our three operating segments as one
reportable segment. We made this determination because a significant percentage of our employees
provide support services (including research and development) to each operating segment; technology
and products from each operating segment are marketed to the same or similar customers; each
operating segment uses the same sales and marketing resources; and each operating segment operates
in the same regulatory environment.
Critical Accounting Policies
Critical accounting policies are those policies that require the application of managements
most challenging subjective or complex judgment, often as a result of the need to make estimates
about the effect of matters that are inherently uncertain and may change in subsequent periods.
Critical accounting policies involve judgments and uncertainties that are sufficiently sensitive to
result in materially different results under different assumptions and conditions. For a detailed
description of our critical accounting policies, see the notes to the financial statements included
in our Annual Report on Form 10-K for the year ended September 30, 2007.
Results of Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
|
|
|
(Dollars in thousands) |
|
2008 |
|
|
2007 |
|
|
$ Increase |
|
|
% Increase |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Drug Delivery |
|
$ |
11,955 |
|
|
$ |
6,205 |
|
|
$ |
5,750 |
|
|
|
93 |
% |
Hydrophilic and Other |
|
|
8,261 |
|
|
|
6,546 |
|
|
|
1,715 |
|
|
|
26 |
% |
In Vitro |
|
|
5,491 |
|
|
|
4,611 |
|
|
|
880 |
|
|
|
19 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
25,707 |
|
|
$ |
17,362 |
|
|
$ |
8,345 |
|
|
|
48 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue. Second quarter revenue was $25.7 million, an increase of $8.3 million or 48%,
compared with the second quarter of fiscal 2007. Revenue included $5.2 million from the acquisition
of Brookwood and $1.1 million from the acquisition of BioFX, which were completed in the fourth
quarter of fiscal 2007. All three operating segments generated revenue growth, as detailed in the
table above and further explained in the narrative below.
Drug Delivery. Revenue in the Drug Delivery segment was $12.0 million in the second quarter of
fiscal 2008, a 93% increase compared with $6.2 million in the prior-year period. The increase in
total revenue reflects a significant increase in research and development revenue from drug
delivery and ophthalmology customers. Our Brookwood business unit generated $5.2 million of revenue
in the second quarter, whereas prior period results do not include any revenue from Brookwood.
Excluding the contribution from Brookwood in the second quarter, Drug Delivery revenue increased 9%
compared with the prior-year period.
Drug Delivery derives a substantial amount of revenue from royalties and license fees and
product sales attributable to Cordis Corporation, a Johnson & Johnson company, on its
CYPHER® Sirolimus-eluting Coronary Stent. The CYPHER® stent incorporates a
proprietary SurModics polymer coating that delivers a therapeutic drug designed to reduce the
occurrence of restenosis in coronary artery lesions.
Drug Delivery royalties and license fees decreased 3%, as increased royalties and license fees
from ophthalmology and drug delivery customers nearly offset a 25% decrease in royalty revenue from
Cordis as a result of lower CYPHER®sales.
Drug Delivery generated total revenue of $1.1 million from Merck royalties, license fees and
research and development activities during the three-month period ended March 31, 2008. In
accordance with accounting for arrangements with multiple elements, we are amortizing the payments
received from Merck over the estimated 16 year economic life of the technology we licensed to
Merck.
The CYPHER® stent, from which we derive a substantial amount of our Drug Delivery
revenue, faces continuing competition from Boston Scientific Corporations Taxus®
drug-eluting stent and Medtronics Endeavor® drug-eluting stent, which are sold
domestically and internationally, and stents from Abbott Vascular and others sold outside the U.S.
In addition,
12
a drug-eluting stent from Abbott is expected to be approved in the U.S. within the next year.
These stents compete or will compete directly with the CYPHER® stent. The Company also
receives a royalty on the Medtronic Endeavor® drug-eluting stent, but the associated
royalty revenue is reflected in the Hydrophilic and Other segment. In addition to competition among
the various players, the total size of the drug-eluting stent market has decreased significantly in
the past eighteen months as a result of concerns about product safety, mostly related to potential
clotting associated with stents. Therefore, future royalty and reagent sales revenue could decrease
due to lower CYPHER® stent sales as a result of the overall market contraction and the
ongoing and expected future competition. We anticipate that quarterly royalty revenue from the
CYPHER® stent may be volatile throughout fiscal 2008 and beyond as the various marketers
of drug-eluting stents continue competing in the marketplace and as others enter the marketplace.
Management expects royalties from the CYPHER® stent to continue to constitute a
substantial portion of our revenue in fiscal 2008. However, whether and the extent to which
royalties from the CYPHER® stent continue to constitute a significant source of revenue
is subject to a number of risks, including intellectual property litigation generally, and
specifically the damages, settlements and mutual agreements that may result from various
infringement suits between Boston Scientific and Cordis in which each has been found to have
violated certain intellectual property rights of the other.
The inclusion of revenue from our Brookwood business unit in Drug Delivery will also impact
the overall revenue and mix in fiscal 2008, as a substantial majority of Brookwood revenue is
comprised of research and development fees.
Hydrophilic and Other. Hydrophilic and Other revenue was $8.3 million in the second quarter of
fiscal 2008, an increase of 26% compared with $6.5 million in the prior-year period, primarily as a
result of 34% growth in royalties and license fees. This increase primarily reflects the Companys
growing portfolio of licensed customers. In contrast to our Drug Delivery segment, where a
significant percentage of revenue is attributable to Cordis, there are several dozen licensees and
an even larger number of coated products generating royalties in this segment. The growth in
royalties principally reflects increased sales of coated products already on the market, and to a
lesser extent newly introduced licensed products. We believe that revenue will likely continue to
increase for the remainder of fiscal 2008; however, the rate of growth will depend upon the timing
and market success of our customers newly released products, as well as the sales of existing
products.
In Vitro. Revenue in the In Vitro segment was $5.5 million in the second quarter of 2008, an
increase of 19% compared with $4.6 million in the prior-year period. The increase was attributable
to increased product sales, mostly as a result of the addition of $1.1 million of BioFX products
sold during the quarter. The increase was partially offset by a decrease in royalties and license
fees. Prior-year results do not include sales of BioFX products, because the acquisition of BioFX
was completed in the fourth quarter of fiscal 2007. In Vitro segment royalties and license fees
decreased principally because of lower underlying sales of licensed products in the second quarter
of fiscal 2008. We anticipate continued growth in product sales for the remainder of fiscal 2008
reflecting particularly the addition of BioFX products, but the rate of growth will depend on the
success of certain product launches. Royalties and license fees likely will not increase. In Vitro
derives a significant percentage of its revenue from GE Healthcare and Abbott Laboratories. Royalty
revenue generated under our diagnostic format patent license agreement with Abbott Laboratories
(the Abbott Agreement) is expected to decline significantly following the expiration of the
licensed patents in December 2008. Consistent with our revenue recognition practices, royalty
revenue is recognized as licensees report it to us, which typically occurs on a quarter lag basis.
Accordingly, we expect royalties generated under the Abbott Agreement to extend into the second
quarter of fiscal 2009.
Product costs. Product costs were $2.2 million in the second quarter of fiscal 2008, compared
with $1.1 million in the prior-year period. The $1.1 million increase in product costs reflects
principally the addition of product sales from BioFX and Brookwood and to a lesser extent a
changing product mix. Overall product margins averaged 54%, compared with 68% reported last year.
The decrease in product margins reflects the changing mix of products sold in the period. In
particular, some of our stabilization and antigen products, genomics slides and Brookwood polymer
products carry lower margins than our reagent products. We anticipate that product margins will
continue to be lower on a year-over-year basis throughout fiscal 2008 when compared to prior-year
results, principally as a result of revenue mix.
Research and development expenses. Research and development expenses were $10.4 million for
the second quarter, an increase of 81% compared with $5.7 million in the prior-year period. The
increase principally reflects the addition of Brookwood and BioFX to our operations, which together
incurred total research and development expenses of $3.5 million in the quarter. In addition,
compensation expenses have increased as we have added personnel to support customer projects and
internal development projects. Our research and development headcount has increased by six and
eleven employees compared with December 31 and March 31, 2007, respectively, not including the
addition of 53 research and development employees related to our Brookwood and BioFX acquisitions.
Also contributing to the increase were a $0.3 million increase in stock-based compensation, higher
costs related to our internal development projects and $0.4 million of out-of-pocket expenses in
connection with our Merck projects, for which we are reimbursed. Research and development expenses
are expected to continue to increase for the remainder of fiscal 2008, reflecting the addition of
Brookwood and BioFX to our operations, and our continued expansion of the research and development
organization. Research and development expenses for our Brookwood business unit, in particular, are
a higher percentage of that units total revenues than for our other business units.
13
Selling, general and administrative expenses. Selling, general and administrative (SG&A)
expenses were $6.0 million for the three-month period ended March 31, 2008, an increase of $3.5
million compared with the prior-year period. The increase principally reflects the addition of
Brookwood and BioFX to our operations, which comprised $1.2 million of SG&A expenses. Our
stock-based compensation expenses increased $1.6 million this quarter principally as a result of recent
transitions on our Board of Directors. We expect SG&A expenses to remain approximately at current
levels for the remainder of fiscal 2008, reflecting the addition of Brookwood and BioFX to our
operations, and continued expansion of our organization to support our anticipated growth.
Other income, net. Other income was $1.2 million in the second quarter of fiscal 2008,
consistent with the prior-year period. Income from investments was $1.1 million, compared with $1.2
million in the prior-year period. The decrease principally reflects lower yields from our
investment portfolio. Offsetting the decrease in investment income was $0.1 million in other
income.
Income tax expense. The income tax provision was $3.3 million in the second quarter of fiscal
2008, compared with $3.6 million in the prior-year period. The effective tax rate was 38.9%,
compared with 38.7% in the prior-year period. This increase is primarily attributable to tax
reserve increases for state tax contingencies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, |
|
|
|
|
|
|
|
(Dollars in thousands) |
|
2008 |
|
|
2007 |
|
|
$ Increase |
|
|
% Increase |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Drug Delivery |
|
$ |
22,723 |
|
|
$ |
12,834 |
|
|
$ |
9,889 |
|
|
|
77 |
% |
Hydrophilic and Other |
|
|
15,815 |
|
|
|
11,823 |
|
|
|
3,992 |
|
|
|
34 |
% |
In Vitro |
|
|
10,998 |
|
|
|
9,445 |
|
|
|
1,553 |
|
|
|
16 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
49,536 |
|
|
$ |
34,102 |
|
|
$ |
15,434 |
|
|
|
45 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue. Total revenue was $49.5 million for the first six months of fiscal 2008, an increase
of $15.4 or 45%, compared with the same period of fiscal 2007. Revenue included $11.7 million from
the acquisitions of Brookwood and BioFX businesses, which were completed in the fourth quarter of
fiscal 2007. All three operating segments generated revenue growth, as detailed in the table above
and further explained in the narrative below.
Drug Delivery. Drug Delivery revenue increased 77% to $22.7 million for the first half of
fiscal 2008 compared with $12.8 million for the same period last year. The increase in total
revenue reflects a significant increase in research and development revenue from drug delivery and
ophthalmology customers, offset partially by lower royalties and license fees. Our Brookwood
business unit generated $9.4 million of revenue in the first six months of fiscal 2008.
Prior-period results do not include any revenue from Brookwood, as the acquisition was completed in
the fourth quarter of 2007. The decrease in Drug Delivery royalties and license fees principally
reflects decreased royalty revenue from Cordis as a result of lower CYPHER® sales.
Substantially offsetting the decrease attributable to CYPHER® was an increase in
royalties and license fees from other drug delivery and ophthalmology customers, including Merck.
Hydrophilic and Other. Hydrophilic and Other revenue increased 34% to $15.8 million compared
with $11.8 million for the same period last year. The growth was driven principally by increased
royalties and license fees as the company continues to grow its licensed customer base.
In Vitro. In Vitro revenue increased 16% to $11.0 million compared with $9.4 million for the
same period last year. The increase was attributable to increased product sales, mostly as a result
of the addition of $2.2 million of BioFX products sold during the period. The increase was
partially offset by a decrease in royalties and license fees. Prior-period results do not include
sales of BioFX products, because the acquisition of BioFX was completed in the fourth quarter of
fiscal 2007. In Vitro segment royalties and license fees decreased principally because the
prior-year results included a settlement related to past due royalties; there was no such
settlement in the first half of fiscal 2008.
Product costs. Product costs were $4.1 million for the six months ended March 31, 2008, an 89%
increase from $2.2 million for the same period last year. Overall product margins averaged 58%
compared with 64% for the comparable period last year. The margin decrease was primarily
attributable to a lower mix of reagent sales which carry higher gross margins than our other
products.
Research and development expenses. Research and development expenses were $19.9 million for
the first six months of fiscal 2008, an increase of 82% compared with $10.9 million for the same
period of fiscal 2007. The increase principally reflects the addition of Brookwood and BioFX to our
operations, which together had total research and development expenses of $6.5 million in the first
six months of fiscal 2008. In addition, compensation expenses have increased as we have
14
added personnel to support customer projects and internal development projects. Our research and
development headcount has increased by eight and eleven compared with September 30 and March 31,
2007, respectively, not including the addition of 53 research and development employees from our
Brookwood and BioFX acquisitions. We have also incurred higher costs related to our internal
development projects, and $1.0 million of out-of-pocket expenses were incurred in connection with
our Merck projects, for which we are reimbursed.
Selling, general and administrative expenses. SG&A expenses were $10.8 million for the first
six months of fiscal 2008, an increase of $6.0 million compared with the prior-year period. The
increase principally reflects the addition of Brookwood and BioFX to our operations, as they
incurred $2.3 million of SG&A expenses. Our stock-based
compensation expenses were $2.0 million higher for the
first six months of fiscal 2008 mainly associated with recent transitions on our Board of
Directors.
Other income, net. Other income was $2.9 million for the first six months of fiscal 2008
compared with income of $2.5 million in the same period of fiscal 2007. Income from investments was
$2.0 million, compared with $2.5 million in the prior-year period. The decrease principally
reflects a decrease in investable cash and lower yields in our investment portfolio. Offsetting the
decrease in investment income was $0.9 million in other income.
Income tax expense. The income tax provision was $6.9 million for the first six months of
fiscal 2008, compared with $7.0 million for the same period in fiscal 2007. The effective tax rate
for the first six months of fiscal 2008 was 39.1%, compared with 37.6% for the same period last
year. The increase in the effective tax rate principally reflects an increase in state tax
contingency reserves in fiscal 2008 and to a release of federal tax reserves in fiscal 2007.
Liquidity and Capital Resources
As of March 31, 2008, the Company had working capital of $48.6 million, of which $37.8 million
consisted of cash, cash equivalents and short-term investments. Working capital increased $20.6
million from the September 30, 2007 level driven principally by cash flow from operations, changes
in income tax assets and liabilities, and the collection of $5.8 million of notes receivable. Our
cash, cash equivalents and short-term and long-term investments totaled $80.9 million at March 31,
2008, an increase of $10.7 million from $70.2 million as of September 30, 2007. The Companys
investments principally consist of U.S. government and government agency obligations and investment
grade, interest-bearing corporate debt securities with varying maturity dates, the majority of
which are five years or less. The Companys policy requires that no more than 5% of investments be
held in any one credit issue, excluding U.S. government and government agency obligations. The
primary investment objective of the portfolio is to provide for the safety of principal and
appropriate liquidity while meeting or exceeding a benchmark (Merrill Lynch 1-3 Year
Government-Corporate Index) total rate of return. Management plans to continue to direct its
investment advisors to manage the Companys investments primarily for the safety of principal for
the foreseeable future as it assesses other investment opportunities and uses of its investments.
We had cash flows from operating activities of approximately $8.9 million in the six months
ended March 31, 2008, compared with $16.5 million the six months ended March 31, 2007. The decrease
compared with prior-year results primarily reflects timing of income tax payments and accounts
receivable increasing in the six months, rather than being a source of cash as it was in the
prior-year period.
In November 2007, our Board of Directors authorized the repurchase of up to $35 million of the
Companys common stock in open-market transactions, private transactions, tender offers, or other
transactions. The repurchase authorization does not have a fixed expiration date. We entered into a
Rule 10b5-1 agreement in January 2008 and during the second quarter of fiscal 2008 purchased 64,200
shares of common stock for $2.6 million at an average price of $40.52 per share. Under the current
authorization the Company has $32.4 million remaining available for authorized share repurchases as
of March 31, 2008.
As of March 31, 2008, we had approximately $236,000 of debt outstanding in connection with our
Brookwood subsidiary. We do not have any material credit agreements established, and we believe
that our existing capital resources will be adequate to fund our operations and material
commitments into the foreseeable future. Our remaining anticipated liquidity needs for fiscal 2008
include but are not limited to the following: milestone payments associated with prior-year
business acquisitions of approximately $3 million; capital expenditures related to the recently
acquired Alabama facility in the range of $13 million to
$18 million (including the $12.2 million paid in
April 2008) and related to our Minnesota facilities in
the range of $4 million to $8 million; and any amounts associated with the repurchase of common
stock under the authorization discussed above.
As of March 31, 2008, the Company did not have any off-balance sheet arrangements with any
unconsolidated entities.
15
Forward-Looking Statements
Certain statements contained in this report and other written and oral statements made from
time to time by the Company do not relate strictly to historical or current facts. As such, they
are considered forward-looking statements that provide current expectations or forecasts of
future events. These forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the use
of terminology such as anticipate, believe, could, estimate, expect, forecast,
intend, may, plan, possible, project, will and similar words or expressions. Any
statement that is not an historical fact, including estimates, projections, future trends and the
outcome of events that have not yet occurred, are forward-looking statements. The Companys
forward-looking statements generally relate to its growth strategy, financial results, product
development programs, sales efforts, sufficiency of capital resources, and the impact of the Cordis
agreement and other significant customer agreements. You should carefully consider forward-looking
statements and understand that such statements involve a variety of risks and uncertainties, known
and unknown, and may be affected by inaccurate assumptions. Consequently, no forward-looking
statement can be guaranteed and actual results may vary materially. The Company undertakes no
obligation to update any forward-looking statement.
Although it is not possible to create a comprehensive list of all factors that may cause
actual results to differ from the Companys forward-looking statements, such factors include, among
others: (i) the Companys significant dependence upon Cordis, which causes our financial results
and stock price to be subject to factors affecting Cordis and its Cypher stent program, including
among others, the rate of market penetration by Cordis, the timing of market introduction of
competing products, product safety or efficacy concerns and intellectual property litigation
generally and specifically the litigation involving Boston Scientific Scimed, Inc. and Cordis in
the U.S. District Court for the District of Delaware in which each was reported in June and July
2005 to have been found to have infringed the patent rights of the other; (ii) frequent
intellectual property litigation in the medical device industry that may directly or indirectly
adversely affect our customers ability to market their products incorporating our technologies;
(iii) failure to obtain intellectual property rights protecting our proprietary technologies, or
the expiration or loss of such rights, could have a material adverse effect on our business,
financial condition and results of operations; (iv) healthcare reform efforts and reimbursement
rates for medical device products that may adversely affect our customers ability to cost
effectively market and sell devices incorporating our technologies; (v) the Companys ability to
attract new licensees and to enter into agreements for additional product applications with
existing licensees, the willingness of potential licensees to sign license agreements under the
terms offered by the Company, and the Companys ability to maintain satisfactory relationships with
its licensees; (vi) the Companys ability to increase the number of market segments and
applications that use its coating technologies through its sales and marketing and research and
development efforts; (vii) the Companys ability to facilitate through strategic investment and
research and development support the creation of new medical device market segments and
applications that incorporate its coating technologies; (viii) market acceptance of products sold
by customers incorporating our technologies and the timing of new product introductions by
licensees; (ix) market acceptance of products sold by customers competitors and the timing and
pricing of new product introductions by customers competitors; (x) the difficulties and
uncertainties associated with the lengthy and costly new product development and foreign and
domestic regulatory approval processes, such as delays, difficulties or failures in achieving
acceptable clinical results or obtaining foreign or FDA marketing clearances, which may result in
lost market opportunities or postpone or preclude product commercialization by licensees; (xi)
efficacy or safety concerns with respect to products marketed by us and our licensees, whether
scientifically justified or not, that may lead to product recalls, withdrawals or declining sales;
(xii) the ability to secure raw materials for reagents the Company sells; (xiii) the Companys
ability to manage successfully clinical trials and related foreign and domestic regulatory
processes for the I-vation intravitreal implant or other acquired products from InnoRx under
development by the Companys ophthalmology division, whether delays, difficulties or failures in
achieving acceptable clinical results or obtaining foreign or FDA marketing clearances postpone or
preclude product commercialization of the intravitreal implant or other acquired products, and
whether the intravitreal implant and any other acquired products remain viable commercial
prospects; (xiv) product liability claims not covered by insurance; (xv) the development of new
products or technologies by competitors, technological obsolescence and other changes in
competitive factors; (xvi) the trend of consolidation in the medical device industry, resulting in
more significant, complex and long term contracts than in the past and potentially greater pricing
pressures; (xvii) the Companys ability to identify suitable businesses to acquire or with whom to
form strategic relationships to expand its technology development and commercialization, its
ability to successfully integrate the operations of companies it may acquire from time to time
(including Brookwood Pharmaceuticals, Inc., and BioFX Laboratories, Inc.) and its ability to create
synergies from acquisitions and other strategic relationships; (xviii) difficulties in bringing our
facilities into compliance with good manufacturing practices or other applicable regulatory
standards may adversely impact our ability to manufacture and supply products, or perform other
services for our customers; (xix) the Companys ability to successfully internally perform certain
product development activities and governmental and regulatory compliance activities with respect
to acquired technology, including InnoRx technology, which activities the Company has not
previously undertaken in any significant manner; (xx) the Companys ability to successfully perform
and earn milestone payments related to contractual milestone criteria in general and specifically
the $288 million in fees and development milestones in the Merck Agreement; (xxi) economic and
other factors over which the Company has no control, including changes in inflation and consumer
confidence; (xxii) acts of God or terrorism which impact the Companys personnel or facilities; and
(xxiii) other factors described in the Risk Factors and other sections of SurModics Annual
Report on Form 10-K, which you are encouraged to read carefully. Many of these factors are outside the control and knowledge of the Company and
could result in increased volatility in period-to-period results. Investors are advised not to
place undue reliance upon the Companys forward-looking information and to consult any further
disclosures by the Company on this subject in its filings with the Securities and Exchange
Commission.
16
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The Companys investment policy requires investments with high credit quality issuers and
limits the amount of credit exposure to any one issuer. The Companys investments principally
consist of U.S. government and government agency obligations and investment-grade, interest-bearing
corporate debt securities with varying maturity dates, the majority of which are five years or
less. Because of the credit criteria of the Companys investment policy, the primary market risk
associated with these investments is interest rate risk. The Company does not use derivative
financial instruments to manage interest rate risk or to speculate on future changes in interest
rates. A one percentage point increase in interest rates would result in an approximate $894,000
decrease in the fair value of the Companys available-for-sale securities as of March 31, 2008, but
no material impact on the results of operations or cash flows. Management believes that a
reasonable change in raw material prices would not have a material impact on future earnings or
cash flows because the Companys inventory exposure is not material.
Although we conduct business in foreign countries, our international operations consist
primarily of sales of reagent and stabilization chemicals. Additionally, all sales transactions are
denominated in U.S. dollars. Accordingly, we do not expect to be subject to material foreign
currency risk with respect to future costs or cash flows from our foreign sales. To date, we have
not entered into any foreign currency forward exchange contracts or other derivative financial
instruments to hedge the effects of adverse fluctuations in foreign currency exchange.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, the Company conducted an evaluation under
the supervision and with the participation of the Companys management, including the Companys
Chief Executive Officer and Chief Financial Officer regarding the effectiveness of the design and
operation of the Companys disclosure controls and procedures, as defined in to Rule 13a-15(e) of
the Securities Exchange Act of 1934 (the Exchange Act),
pursuant to Rule13a-15(b) of the Exchange
Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded
that the Companys disclosure controls and procedures were effective as of such time.
Changes in Internal Controls
There were no changes in the Companys internal control over financial reporting that occurred
during the period covered by this report that have materially affected, or are reasonably likely to
materially affect, the Companys internal control over financial reporting.
17
PART II OTHER INFORMATION
Item 1. Legal Proceedings.
There have been no material developments in the legal proceedings previously disclosed in the
Companys Form 10-K for the fiscal year ended September 30, 2007.
Item 1A. Risk Factors.
There have been no material changes from risk factors as previously disclosed in the Companys
Form 10-K for the fiscal year ended September 30, 2007 in response to Item 1A to Part I of Form
10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
(c) Issuer Purchases of Equity Securities
The following table presents information with respect to purchases of common stock of the
Company made during the three months ended March 31, 2008, by the Company or on behalf of the
Company or any affiliated purchaser of the Company, as defined in Rule 10b-18(a)(3) under the
Exchange Act.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) |
|
(d) |
|
|
|
|
|
|
|
|
|
|
Total Number |
|
Dollar |
|
|
|
|
|
|
|
|
|
|
of Shares |
|
Value of |
|
|
|
|
|
|
|
|
|
|
Purchased |
|
Shares that |
|
|
|
|
|
|
|
|
|
|
as Part of |
|
May Yet Be |
|
|
(a) |
|
(b) |
|
Publicly |
|
Purchased |
|
|
Total Number |
|
Average |
|
Announced |
|
Under the |
|
|
of Shares |
|
Price Paid |
|
Plans or |
|
Plans or |
Period |
|
Purchased(1) |
|
Per Share |
|
Programs |
|
Programs(2) |
|
1/01/08 1/31/08 |
|
|
0 |
|
|
NA |
|
NA |
|
NA |
2/01/08 2/29/08 |
|
|
0 |
|
|
NA |
|
NA |
|
NA |
3/01/08 3/31/08 |
|
|
67,390 |
|
|
$ |
40.50 |
|
|
|
64,200 |
|
|
$ |
32,398,599 |
|
|
Total |
|
|
67,390 |
|
|
$ |
40.50 |
|
|
|
64,200 |
|
|
$ |
32,398,599 |
|
|
|
|
|
(1) |
|
The purchases in this column included shares repurchased as part of our
publicly announced program and in addition include 3,190 shares that were
repurchased by the Company to satisfy tax withholding obligations in
connection with so-called stock swap exercises related to the vesting of
restricted stock awards. |
|
(2) |
|
On November 15, 2007, our Board of Directors announced the authorization of
the repurchase of $35 million of its outstanding common stock. As of March
31, 2008, we have repurchased 64,200 shares at an average price of $40.52 per
share. Under the current authorization the Company has $32.4 million
available for authorized share repurchases as of March 31, 2008, and such
authorization has no expiration date. |
Item 3. Defaults Upon Senior Securities.
Not Applicable.
Item 4. Submission of Matters to a Vote of Security Holders.
The information disclosed under Part II Item 4 of the Companys Quarterly Report on Form 10-Q
for the period ended December 31, 2007 is incorporated herein by reference.
Item 5. Other Information.
Not Applicable.
18
Item 6. Exhibits.
|
|
|
Exhibit |
|
Description |
3.1
|
|
Restated Articles of Incorporation, as amended incorporated by
reference to Exhibit 3.1 of the Companys Quarterly Report on Form
10-QSB for the quarter ended December 31, 1999, SEC File No.
0-23837 |
|
|
|
3.2
|
|
Restated Bylaws incorporated by reference to Exhibit 3.2 of the
Companys Annual Report on Form 10-K for the fiscal year ended
September 30, 2007, SEC File No. 0-23837 |
|
|
|
10.1
|
|
Real Estate Purchase Agreement
between Brookwood Pharmaceuticals, Inc., and Belk, Inc., dated March
11, 2008**
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer Pursuant to Section 302
of Sarbanes-Oxley Act of 2002** |
|
|
|
31.2
|
|
Certification of Chief Financial Officer Pursuant to Section 302
of Sarbanes-Oxley Act of 2002** |
|
|
|
32.1
|
|
Certification of Chief Executive Officer Pursuant to Section 906
of Sarbanes-Oxley Act of 2002** |
|
|
|
32.2
|
|
Certification of Chief Financial Officer Pursuant to Section 906
of Sarbanes-Oxley Act of 2002** |
19
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
SurModics, Inc.
|
|
Date: May 9, 2008 |
By: |
/s/ Philip D. Ankeny
|
|
|
|
Philip D. Ankeny |
|
|
|
Senior Vice President and Chief Financial Officer
(duly authorized officer and principal financial officer) |
|
20
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
EXHIBIT INDEX TO FORM 10-Q
For the Quarter Ended March 31, 2008
SURMODICS, INC.
|
|
|
Exhibit |
|
Description |
3.1
|
|
Restated Articles of Incorporation, as amended incorporated by reference to Exhibit 3.1 of
the Companys Quarterly Report on Form 10-QSB for the quarter ended December 31, 1999, SEC File
No. 0-23837 |
|
|
|
3.2
|
|
Restated Bylaws incorporated by reference to Exhibit 3.2 of the Companys Annual Report on
Form 10-K for the fiscal year ended September 30, 2007, SEC File No. 0-23837 |
|
|
|
10.1
|
|
Real Estate Purchase Agreement
between Brookwood Pharmaceuticals, Inc., and Belk, Inc., dated March
11, 2008**
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002** |
|
|
|
32.1
|
|
Certification of Chief Executive Officer Pursuant to Section 906 of Sarbanes-Oxley Act of 2002** |
|
|
|
32.2
|
|
Certification of Chief Financial Officer Pursuant to Section 906 of Sarbanes-Oxley Act of 2002** |
21
exv10w1
EXHIBIT 10.1
REAL ESTATE PURCHASE AND SALE AGREEMENT
THIS
AGREEMENT is made this 11th day of March, 2008, by and between:
|
|
|
SELLER:
|
|
BELK, INC. |
|
|
2801 West Tyvola Road |
|
|
Charlotte, North Carolina 28217 |
|
|
Attention: Bradley B. Wood, Vice President |
|
|
(Seller) |
|
|
|
PURCHASER:
|
|
BROOKWOOD PHARMACEUTICALS, INC., or its assigns |
|
|
756 Tom Martin Drive |
|
|
Birmingham, Alabama 35211 |
|
|
Attention: Arthur J. Tipton, President |
|
|
(Purchaser) |
WITNESSETH:
WHEREAS, pursuant to that certain Lease Agreement dated December 1, 1985 recorded on January
9, 1986, in Real Volume 2980, Page 578, as amended by the First Supplemental Lease Agreement dated
September 5, 1986 recorded on September 5, 1986, in Real Volume 2980, Page 873; the Second
Supplemental Lease Agreement dated September 1, 1987 recorded January 25, 1988 in Real Volume 3321,
Page 56; the Third Supplemental Lease Agreement dated November 1, 1988 recorded November 30, 1988
in Real Volume 3509, Page 862; the Fourth Supplemental Lease Agreement dated July 24, 1991 and the
Fifth Supplemental Lease Agreement dated November 17, 1997; and all recorded in the Probate Office
of Jefferson County, Alabama as set forth above (collectively the Lease) between Parisian, Inc.
and the Industrial Development Board of the City of Birmingham (the IDB); and
WHEREAS, on March 4, 2006 Parisian, Inc., an Alabama corporation assigned the lease to McRaes
of Alabama, Inc., an Alabama corporation (formerly Pizitz, Inc.) which assignment was recorded on
March 15, 2006 in Book LR 200605, Page 8336 in the Office of the Judge of Probate of Jefferson
County, Alabama; and
WHEREAS, on March 6, 2006 McRaes of Alabama, Inc., an Alabama corporation amended its
Articles of Incorporation to change its name to Parisian Stores, Inc., an Alabama corporation which
amendment was filed on March 11, 2006 in Book LR 200605, Page 325 in the Office of the Judge of
Probate of Jefferson County, Alabama; and
WHEREAS, On October 2, 2006 Parisian Stores, Inc., an Alabama corporation merged with Belk,
Inc. (Seller) a Delaware corporation as evidenced by the Certificate of Merger filed on October
2, 2006 in the Office of the Secretary of State of the State of Alabama; and
1
WHEREAS, Seller is the lessee of that certain real estate located at 750 Lakeshore Parkway, in
the City of Birmingham, Jefferson County, Alabama, consisting of an office building and warehouse
facility, as more particularly described in the attached Exhibit A and identified on the
attached Exhibit A-1 (the Real Property); and
WHEREAS, Seller has an option to purchase the Real Property under the terms of the Lease (the
Purchase Option); and
WHEREAS, Seller has agreed to exercise the Purchase Option and to convey its interest in the
Real Property and the Personal Property, as hereinafter defined, to Purchaser, and Purchaser has
agreed to purchase the same, upon the terms and conditions set forth in this Agreement.
AGREEMENT:
For and in consideration of the representations, covenants, and agreements herein contained,
the parties hereto agree as follows:
1. PURCHASE AND SALE. Seller hereby agrees to sell, transfer, convey, assign and
deliver to Purchaser, and Purchaser hereby agrees to purchase from Seller, on the Closing Date,
as hereinafter defined, the following at the purchase price and upon the terms and conditions
hereinafter set forth:
(a) The Real Property described in the attached Exhibit A, together with all
buildings, improvements, walls, fences, signage, shrubbery, plantings and fixtures thereon, at the
purchase price and upon the terms and conditions hereinafter set forth. The Real Property to be
sold hereunder shall include all rights, ways, alleys, privileges, easements, appurtenances, and
advantages thereto belonging or in any wise appurtenant.
(b) Any and all equipment, machinery, fixtures, tools, signs, systems, supplies, inventories,
and other tangible personal property owned by Seller, including without limitation furniture,
furnishings, fixtures, carpeting, heating, lighting, plumbing, water, sewer, ventilating,
electrical, gas, heating, air conditioning, communication, fire protection, security and
light/safety fixtures, equipment and systems, water heaters, furnaces, heating controls and motors,
incinerating, disposal, cleaning, maintenance, janitorial, landscaping equipment, and other items
located on the Real Property (collectively, the Personal Property). Notwithstanding the above,
the list of property itemized in Schedule 1(b) shall not be included in the sale (the Excluded
Personal Property).
(c) Any and all transferable licenses, permits, certificates, approvals, authorizations,
variances and consents, if any, issued or granted by governmental or quasi-governmental bodies,
respecting the ownership, use or operation of the Real Property (collectively, the Licenses and
Permits).
(d) At the option of Purchaser, any and all management and leasing agreements, if any,
service, supply, equipment rental, janitorial, security, landscaping and other contracts related to
the ownership, operation, leasing or use of the Real Property or the Personal Property,
as well as warranties for the improvements on the Real Property, including without limitation
the mechanical systems, roofing and paving (collectively, the Service Contracts).
2
Collectively, the Real Property, Personal Property, Licenses and Permits and Service Contracts may
hereinafter be referred to as the Property.
In connection with the foregoing, Seller shall, at its expense, be responsible for properly
exercising its Purchase Option prior to the Closing in order that it may subsequently convey fee
simple title to the Property to Purchaser at the Closing.
2. PURCHASE PRICE. The Purchase Price of the Property shall be Twelve Million Fifty
Thousand and 00/100 Dollars ($12,050,000.00), to be paid as follows:
(a) Within ten (10) business days following last execution of this Agreement, Purchaser shall
deposit with Lawyers Title Insurance Corporation (the Escrow Agent) the sum of One Hundred
Thousand and 00/100 Dollars ($100,000.00) as earnest money (the Earnest Money), which Earnest
Money shall be held in trust in an interest bearing account (in favor of Purchaser) and shall be
applied to the Purchase Price at the Closing.
(b) The Purchase Price shall be paid to Seller at Closing, subject to adjustments as provided
for herein, in cash or by cashiers or certified check or by wire transfer of funds.
3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF SELLER. Seller hereby represents and
warrants to Purchaser the following, which shall be true and correct at the time of Closing, which
are material inducements for Purchaser entering into this Agreement, and which shall survive the
Closing:
(a) Seller is a corporation duly organized, validly existing, and in good standing under the
laws of the State of Delaware, is authorized to transact business and is in good standing under the
laws of the State of Alabama.
(b) The execution, delivery and performance of this Agreement by Seller has been duly
authorized by all requisite action on the part of Seller, and Seller shall at Closing have the full
right and authority to enter into, perform and consummate its obligations under this Agreement,
without any qualification, and without the necessity of any other consent.
(c) The obligations and undertakings of Seller under this Agreement do not and will not
violate or conflict with any agreement to which Seller is a party or by which Seller or the
Property is bound.
(d) Without warranting the completeness, conclusions or methodology of any documents produced
by third parties, to the best of Sellers knowledge, all of the information and data delivered and
to be delivered to Purchaser by Seller under this Agreement are, and at Closing will be, true and
correct in all material respects.
3
(e) Other than the Personal Property located on or in the Property on February 13, 2008 (less
the Excluded Personal Property), there is no other personal property owned by Seller relating to
the Real Property.
(f) Seller will in accordance with Section 5 of this Agreement, provide Purchaser with
true, correct and complete copies of all Licenses and Permits it currently has relating to the
Property. Seller has no applicable Licenses or Permits other than those listed on Schedule
3(f) attached hereto. All amounts payable by Seller in connection with such Licenses and
Permits have been paid through the last date due and there is no material default existing and
continuing thereunder by Seller.
(g) Attached hereto as Schedule 3(g) is a list of all Service Contracts related to the
ownership, operation, leasing or use of the Property. Seller has, or will in accordance with
Section 5 of this Agreement, provide Purchaser with true, correct and complete copies of
the Service Contracts listed in Schedule 3(g). All amounts payable by Seller under such contracts
have been paid through the last date due and there is no material default existing and continuing
thereunder by Seller, or to the best of Sellers knowledge, the other party thereto.
(h) Except for the Purchase Option, there are no recorded or unrecorded contracts and/or
options pertaining to or affecting the sale of the Property, or any part thereof, among parties
other than Seller and Purchaser.
(i) To the best of Sellers knowledge, there are no Hazardous Materials, as hereinafter
defined, located in, on, or under the Property. Seller is not a generator of any such Hazardous
Materials and has conducted its activities on and from the Property in full compliance with all
hazardous waste emission, reporting, and removal requirements imposed by applicable law. To the
best of Sellers knowledge, there are not now, nor has there ever been, any underground or
aboveground storage tanks located at or within the Property. Seller has not used or operated the
Property in any manner for the storage, use, treatment, manufacture or disposal of any Hazardous
Materials, and, to the best of Sellers knowledge and belief, the Property has never been used or
operated for the storage, use, treatment, manufacture or disposal of any Hazardous Materials. For
purposes hereof, Hazardous Materials shall mean any substance, material, waste, gas, or
particulate matter which is regulated by any local governmental authority, the State of Alabama, or
the United States Government, including, without limitation, any material or substance which is (i)
defined as a contaminant, pollutant, hazardous waste, hazardous material, hazardous
substance, extremely hazardous waste, or restricted hazardous waste under any provision of
Alabama law; (ii) petroleum products; (iii) asbestos; (iv) polychlorinated biphenyl; (v)
radioactive material; (vi) designated as a hazardous substance pursuant to Section 311 of the
Clean Water Act, 33 U.S.C. §1251 et seq. (33 U.S.C. §1317); (vii) defined as a hazardous
waste pursuant to Section 1004 of the Resource Conservation & Recovery Act, 42 U.S.C. §6901
et seq (42 U.S.C. §6903); or (viii) defined as a hazardous substance pursuant to
Section 101 of the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C.
§9601 et seq. (42 U.S.C. §9601).
(j) Seller is the present owner of the leasehold interest created under the Lease, and there
are no parties in possession of the Property other than Seller. The IDB is the present fee simple
titleholder of the Property.
4
(k) Seller has performed all obligations required to be performed by it and is not in default
under the Lease or any indenture, mortgage, security agreement or other agreement to which Seller
is or has been subject as a party with respect to the Property.
(l) Except as disclosed in Section 10 below and as set forth in Schedule 3(g),
no contract or agreement of any kind including, without limitation, real estate leasing and
brokerage contracts, and contracts for servicing, operating or managing the Property, will be
effective and binding upon the Property or Purchaser.
(m) To the best of Sellers knowledge, there is no threatened impairment of the sewer, water,
electric and telephone services provided to the Property.
(n) To the best of Sellers knowledge, there are no unpaid improvement liens, special
assessments or library or fire dues affecting the Property, and there are no actions, suits or
proceedings, governmental or otherwise, including without limitation condemnation or eminent domain
proceedings, pending or threatened against or affecting the Property, or affecting Sellers ability
to perform its obligations under this Agreement, and there are no such actions, suits or
proceedings pending, contemplated or threatened by Seller in connection with the Property; and from
and after the date of this Agreement except for actions to enforce the terms of this Agreement,
Seller shall not commence or allow to be commenced, on its behalf, any action, suit or proceeding
with respect to the Property without the prior written consent of Purchaser, which consent shall
not be unreasonably withheld or delayed.
(o) Seller is not a foreign person as that term is defined in Section 1445 of the Internal
Revenue Code, and Seller shall execute an affidavit to such effect in the form to be provided by
Purchaser, failing which Purchaser may proceed with the withholding provisions as provided by
applicable law. Seller shall indemnify Purchaser and its agents against any liability or cost,
including reasonable attorneys fees, in the event that this representation or the affidavit
provided by Seller at the Closing is false.
(p) [Intentionally Deleted]
(q) Seller has not made a general assignment for the benefit of creditors, filed any voluntary
petition in bankruptcy or, to the best of Sellers knowledge, suffered the filing of an involuntary
petition by Sellers creditors, suffered the appointment of a receiver to take possession of all,
or substantially all, of Sellers assets, suffered the attachment or other judicial seizure of all,
or substantially all, of Sellers assets, admitted in writing its inability to pay its debts as
they generally come due or made an offer of settlement, extension or composition to its creditors
generally.
(r) There are no leases or other occupancy rights granted by Seller relating to or affecting
the Property.
(s) Seller has not filed, and has not retained anyone to file, notices of protest against, or
to commence actions to review ad valorem tax assessments against the Real Property which are
currently pending. During the term of this Agreement, Seller will not settle or compromise
any of foregoing without the prior written consent of Purchaser, not to be unreasonably
withheld, conditioned or delayed.
5
(t) Seller shall keep and maintain, at its sole cost and expense, until the earlier of the
Closing or the termination of this Agreement, the following insurance with respect to the Real
Property (including the improvements thereon): (i) property and casualty insurance in an amount not
less than the Purchase Price, and (ii) public liability insurance in a commercially reasonable
amount. All policies of insurance required to be carried by Seller hereunder shall be issued by
responsible insurance companies which are licensed to do business in the State of Alabama and have
a Bests rating of at least A.
(u) Seller shall not remove any Personal Property other than the Excluded Property from the
Real Property prior to the Closing, except for the replacement of items of at least equal value,
which replacement items shall be included in this sale.
(v) From and after the date this Agreement is fully executed, Seller will:
|
(i) |
|
except as may be required by law, not perform any grading,
excavation, construction, or remove any improvements or personal property
(other than the Excluded Personal Property), or make any other change or
improvement upon or about the Property; |
|
|
(ii) |
|
not create or incur, or suffer to exist, any mortgage, lien,
pledge, or other encumbrances in any way affecting the Property other than the
Permitted Exceptions; |
|
|
(iii) |
|
not commit any waste or nuisance upon the Property; |
|
|
(iv) |
|
not violate any laws, ordinances, regulations, and restrictions
affecting the Property and its use; |
|
|
(v) |
|
not execute any leases affecting the Property without the prior
written approval of Purchaser; |
|
|
(vi) |
|
not default under the Lease; |
|
|
(vii) |
|
through Closing maintain, preserve and protect the Property in
the same condition existing as of the date of this Agreement; and |
|
|
(viii) |
|
promptly notify Purchaser in writing of any event or circumstance of which
Seller becomes aware which materially affects Sellers ability to timely
perform its covenants, or materially affects the truth of any representation or
warranty made by Seller under this Agreement. |
(w) At or prior to Closing, Seller shall satisfy any and all claims for mechanics or
materialmens liens against the Property or any part thereof incurred or suffered by Seller, and
shall indemnify and hold harmless and protect the Purchaser from any and all loss or liability
from such claims, including, without limitation, reasonable attorneys fees and court costs.
6
(x) Seller shall cooperate in good faith with Purchaser in its application for all permits,
licenses, approvals and other authorizations, including any re-zoning (or zoning variance) and
resubdivision, with regard to its purchase and proposed use of the Property.
(y) As used herein, the term knowledge with respect to any party shall mean the actual
knowledge of such party.
4. TITLE INSURANCE.
(a) Within ten (10) days following Sellers execution of this Agreement, Seller, at Sellers
expense, shall obtain and deliver to Purchaser a title commitment issued by Burr & Forman Title
Company, as agent of Lawyers Title Insurance Corporation (the Title Company) for the issuance of
an owners title policy, ALTA Owners Policy Form B dated October 17, 1992, in the amount of the
Purchase Price (the Title Commitment), covering title to the Property at a date not earlier than
the date hereof and showing fee simple title vested in Seller, subject only to taxes for the
current tax year and those permitted exceptions approved by Purchaser (collectively the Permitted
Exceptions). Purchaser shall review the Title Commitment and make its objections to title within
the Inspection Period set forth in Section 5. Any matters of record which are not
objected to within the Inspection Period shall be deemed Permitted Exceptions. If Seller is unable
to cure any exception to title that is not a Permitted Exception or satisfy any title requirement
within the earlier of (i) fourteen (14) days following written notice by Purchaser to Seller of
such title matter, or (ii) the Closing Date, then Purchaser may (A) terminate this Agreement upon
written notice to Seller, whereupon the Earnest Money plus interest shall be returned to Purchaser
upon demand and the parties shall have no further rights or obligations hereunder, or (B) elect to
purchase the Property without offset against the Purchase Price for any such exception.
(b) Any exceptions or requirements appearing on any updated title commitment which were not
reflected in the initial Title Commitment shall be cured or satisfied by Seller, unless waived by
Purchaser in writing.
5. INSPECTION.
(a) Within ten (10) days following Sellers execution of this Agreement, Seller shall deliver
to Purchaser copies, if any, of all existing agreements, leases, site plans, soils and
environmental reports, traffic studies, title policies, surveys, as-built construction plans and
specifications for any improvements located on the Property, governmental permits, notices of
violations of law, a copy of the Propertys tax bill for the current year and any prior year,
tests, and other reports relating to the Property, and reports or other documents of any kind or
nature pertaining to the Property, which are in Sellers possession or under Sellers control
(collectively, the Due Diligence Material). The Inspection Period, as hereinafter defined,
shall be extended on a day per day basis for each day that Seller delays beyond such ten (10) day
period in delivering the Due Diligence Material to Purchaser. Prior to Closing, Seller shall, upon
request of Purchaser, provide such other documents and information relating to the Property as
Purchaser may reasonably request and which are in Sellers possession. Purchaser may rely on
all reports and materials delivered by Seller under this Section 5.
7
(b) Purchasers obligations under this Agreement are hereby conditioned upon, at its sole cost
and expense (except as otherwise provided herein), satisfactory completion of inspections of the
Property in order to determine the feasibility of the Property for its proposed use, including
title, survey, structural and systems reports, environmental tests, examination of topography,
local building restrictions, utility availability and soil conditions, engineering reports and
preparation of plans and specifications and obtaining adequate financing and such other
observations and inspections of the Property as are deemed necessary or appropriate by Purchaser.
Seller agrees to provide to Purchaser, its contractors, agents and employees reasonable access to
the Property until Closing for such purposes and acknowledges that such inspections and examination
may involve soil borings and samplings and similar invasive procedures. Seller agrees to make
available relevant personnel to answer any inquiries reasonably submitted by Purchaser concerning
the Property.
(c) Purchaser shall have sixty (60) days from the date of last execution of this Agreement in
order to make such inspections as set forth in Paragraph 5(b) above and to obtain any necessary
permits with respect to its proposed use. Such sixty (60) day period is herein referred to as the
Inspection Period. In the event Purchaser is not satisfied with the results of such reports,
tests, examinations, observations and inspections for any reason whatsoever, Purchaser may
terminate this Agreement by giving written notice to Seller at or prior to the expiration of the
Inspection Period, and the Earnest Money plus interest shall be returned to Purchaser upon demand,
and the parties shall have no further rights or obligations hereunder.
6. CONDITIONS OF CONTRACT. This Agreement and the obligations of Purchaser to
consummate the transaction contemplated hereby are conditioned and contingent upon the following:
(a) Title. Delivery to Purchaser of good, marketable and insurable title to Property
such that the Title Company (by and through the Escrow Agent) will insure the same at standard
rates on ALTA Owners Policy Form B dated October 17, 1992, subject only to ad valorem taxes for
the current year and the Permitted Exceptions. The standard exceptions within the policy for
mechanics and materialmens liens, the survey exception and the gap coverage exception shall all
be deleted.
(b) Representations. The truth and accuracy as of the date of Closing of each and
every representation and warranty and the performance of each Seller covenant contained in this
Agreement.
(c) Condition of Property. Seller shall not have caused or permitted any adverse
change in the condition of the Property, ordinary wear and tear excepted.
(d) Closing Documents. The delivery to Purchaser of the Closing Documents listed in
Section 8(c).
8
(e) [Intentionally Deleted]
(f) [Intentionally Deleted]
If any of the above conditions are not met on or before the Closing Date, Purchaser may elect
to (i) waive the same, (ii) extend the Closing Date for up to sixty (60) days until all conditions
have been met, or (iii) terminate and rescind this Agreement by giving written notice to Seller of
its intention to rescind, whereupon this Agreement shall be null and void and of no further force
and effect and the Earnest Money plus interest shall be returned to Purchaser upon demand.
7. SURVEY. Within ten (10) days following Sellers execution of this Agreement,
Seller, at Sellers expense, shall obtain and deliver to Purchaser an ALTA survey of the Property
(the Survey). If Purchaser shall disapprove of any survey matter, Purchaser may either (i) treat
such objection as a title objection and request that it be cured as set forth in Section 4,
or (ii) Purchaser shall have the right to terminate this Agreement, whereupon this Agreement shall
be null and void and of no further force and effect and the Earnest Money plus interest shall be
returned to Purchaser upon demand. At Purchasers election, the legal description to be included
in the Deed, as hereinafter defined, shall be the legal description set forth on the Survey.
8. CLOSING.
(a) The consummation of the sales transaction described in this Agreement is referred to
herein as the Closing.
(b) The Closing Date shall occur within thirty (30) days following the expiration of the
Inspection Period set forth in Section 5 hereinabove, or on such earlier date as the
parties may mutually agree.
(c) At the Closing, Seller shall deliver to Purchaser the following:
(i) A deed in Statutory Warranty or Special Warranty form (or such form as is used in
connection with the conveyance of the Property by the IDB to Seller) fully executed and
acknowledged by Seller conveying the Property to Purchaser (the Deed).
(ii) A bill of sale in special or limited warranty form, fully executed and
acknowledged by Seller, conveying title to all Personal Property, free and clear of all
liens, charges and encumbrances.
(iii) An assignment in quitclaim form, fully executed and acknowledged by Seller,
assigning all of Sellers right, title and interest in and to the Licenses and Permits (to
the extent assignable), free and clear of all liens, charges and encumbrances.
(iv) At the option of Purchaser, an assignment in quitclaim form, fully executed and
acknowledged by Seller, assigning all of Sellers right, title and interest in and to the
Service Contracts, free and clear of all liens, charges and encumbrances;
9
provided, however, that Purchaser shall not be obligated to assume any of Sellers
obligations under the Service Contracts, and Purchaser may elect not to accept an assignment
of any one or all of the Service Contracts.
(v) A certificate stating that the representations and warranties of Seller set forth
herein are true and correct as of Closing.
(vi) A Non-Foreign Affidavit.
(vii) An affidavit certifying that, as of the date of Closing, no improvements or
repairs have been made in or to the Property nor any work done which has not been fully paid
for, nor have any materials been furnished or delivered to the Property which have not been
fully paid for, and that no contract has been made or entered into or anything done,
suffered, or permitted in relation to the Property the consequences of which will cause or
allow any lien or claim of lien to be made against the Property.
(viii) An affidavit that there are no judgments, liens or other claims against the
Property, nor any claims or disputes concerning boundary lines, which would in any manner
create an encumbrance upon the Property.
(ix) A signature counterpart to a settlement statement.
(x) Such other documents and affidavits reasonably required by the Title Company or
Purchaser as may be necessary or customary to consummate the transactions contemplated
herein.
(d) At the Closing, Purchaser shall deliver to Seller the following:
(i) The funds required to be delivered by it at Closing by wire transfer.
(ii) A signature counterpart to a settlement statement.
(iii) Such other documents and affidavits reasonably required by the Title Company or
Seller as may be necessary or customary to consummate the transactions contemplated herein.
(e) Personal property and ad valorem real estate taxes (collectively, the Taxes) shall be
prorated at Closing based on the latest information available with the understanding that municipal
taxes are paid in advance and county taxes in arrears. If the Taxes are prorated based on an
estimate at the Closing, then Seller and Purchaser agree to readjust such proration at the request
of either party upon the establishment of the actual amount by the applicable taxing authorities.
Notwithstanding anything contained in this Agreement to the contrary, Seller and Purchaser agree
that (i) Purchaser shall have no obligation or liability for payment of any so-called rollback
taxes which may be payable by virtue of Alabama Code Section 40-7-25.3 on account of any present
current use assessment of the Property; and (ii) if any such rollback taxes are levied or
assessed on Seller, Purchaser or the Property, whether prior to the Closing or otherwise, Seller
shall be solely responsible for and shall assume payment of same (and if
Purchaser has paid same, Seller shall reimburse Purchaser for the amount paid by Purchaser).
These obligations shall survive the Closing.
10
(f) Utilities shall not be prorated at Closing. Purchaser shall be responsible for
establishing its own utility accounts as of the Closing Date. Seller shall be entitled to a refund
of all existing utility deposits. Seller shall remain responsible for utility bills received
post-Closing that relate to the period prior to the Closing Date, and Purchaser shall be
responsible for all utility bills relating to the Closing Date and thereafter.
(g) Seller shall pay for the title insurance premium and all costs and expenses associated
with the issuance of the Title Commitment and policy; provided, however, that in the event
Purchaser requires a mortgagee title insurance policy in connection with the Closing, Purchaser and
Seller shall each pay one-half (1/2) of the cost of the title insurance premium. Seller shall pay
all costs and expenses associated with the Survey. Purchaser shall pay all costs and expenses
relating to its inspection of the Property and the costs of recording the Deed. Seller and
Purchaser shall each pay one-half (1/2) of any escrow fees payable in connection with the
transactions contemplated by this Agreement.
9. DEFAULT.
(a) In the event all conditions to Purchasers obligation to close have been satisfied and
Purchaser fails to close the transaction, Seller may terminate this Agreement, whereupon the
Earnest Money shall be forfeited as liquidated damages to Seller and the Seller shall have no other
remedy or rights against Purchaser. The foregoing remedy shall be Sellers sole remedy in the
event of Purchasers default.
(b) In the event all conditions to Sellers obligation to close have been satisfied and Seller
fails to close the transaction, Purchaser may at its sole discretion, either (i) enforce this
Agreement and the sale and purchase provided for herein according to its terms by all means
available at law or equity, including specific performance, or (ii) terminate this Agreement and
receive a full refund of all Earnest Money, and Seller shall reimburse Purchaser for its reasonable
out-of-pocket costs.
10. BROKERAGE. Seller and Purchaser acknowledge that EGS Commercial Real Estate, as a
representative of Seller, and Graham & Company, as a representative of Purchaser (collectively, the
Brokers), are the only brokers, agents, or sales persons involved in the transactions
contemplated by this Agreement. Seller shall be responsible for paying any and all real estate
commissions due to the Brokers, which commissions will be split equally between the Brokers and
will be paid at Closing. Seller and Purchaser each agree to indemnify and defend and hold the
other party harmless from and against any other real estate commission liability or claim including
attorneys fees or expenses whether for negotiations, trial or appeal, including appellate fees or
expenses incurred by either party as a result of the other partys breach of this representation
and warranty made pursuant to this Section 10. Seller and Purchaser will execute and
deliver an affidavit at Closing to satisfy the requirements of Alabama Code Section 35-11-450, et.
seq. This provision shall survive closing.
11
11. RISK OF LOSS.
(a) The risk of loss or damage to the Property and any improvements thereon shall remain with
the Seller until the Closing shall have occurred. Seller shall maintain the Insurance Policies and
shall otherwise insure the Property against fire, hazard and other casualty during the term hereof.
(b) In the event of a casualty, Seller shall repair or replace any damage caused to the
Property by fire or other casualty prior to Closing; provided, however, that the Closing Date shall
be extended for such reasonable time as shall allow such restoration, or at Purchasers option, the
transaction shall be closed and Seller shall assign to Purchaser all proceeds under its insurance
policy and allow Purchaser a credit for the amount of the deductible. If Seller does not complete
its restoration or repair within thirty (30) days of the casualty event, Purchaser shall be
entitled to terminate this Agreement, receive a full refund of the Earnest Money and Seller shall
reimburse Purchaser for its reasonable out-of-pocket costs.
12. NOTICES. All notices and other communications provided for herein shall be
validly given, made or served if in writing and (i) delivered personally or (ii) sent by United
States certified mail, return receipt requested, postage prepaid, or (iii) sent by a nationally
recognized overnight courier service, addressed as set forth on the first page or to such other
address as shall be furnished in writing by any party to the other parties. Notice shall be
effective when received. Copies of all notices and other communications provided hereunder shall
be sent to counsel for Seller and Purchaser as follows:
If to Sellers counsel:
W. Benjamin Johnson, Esq.
Burr & Forman, LLP
420 North 20th Street, Suite 3400
Birmingham, Alabama 35203
If to Purchasers counsel:
Matthew W. Grill, Esq.
Maynard, Cooper & Gale, P.C.
1901 Sixth Avenue North
2400 Regions/Harbert Plaza
Birmingham, Alabama 35203
13. TAX-DEFERRED EXCHANGES. Each party acknowledges that the other may wish to
structure this transaction in such a manner so as to effectuate a tax-deferred exchange.
Accordingly, notwithstanding anything to the contrary contained herein, each party shall have the
right to assign its rights to a third party for the purpose of effectuating a tax-deferred
exchange. The non-exchanging party shall cooperate in all reasonable respects with the
12
exchanging party to effectuate its tax-deferred exchange; provided, however, that (i) the
Closing shall not be extended or delayed by reason of such exchange, and (ii) the non-exchanging
party shall not be required to incur any additional cost or expense as a result of such exchange.
14. CONFIDENTIALITY. The terms and conditions of this Agreement and all writings,
discussions, and negotiations in connection with the transaction contemplated by this Agreement
(including, without limitation, the fact that discussions and negotiations have been conducted by
the parties), shall remain strictly confidential and shall not be disclosed by either party without
the prior written consent of the other party; except as may be required by law, attorneys,
accountants and tax preparers. Seller acknowledges that Purchaser is seeking to obtain certain
economic incentives from the City of Birmingham, Jefferson County and the State of Alabama relating
to its purchase and use of the Property, and Seller agrees that disclosure to and by one or more of
these governmental entities in connection therewith is expressly permitted under this Section
14.
15. MISCELLANEOUS PROVISIONS.
(a) Assignment. Purchaser shall have the right to assign this Agreement to any
related corporation, limited liability company, partnership, person, persons or other entity in
which Purchaser, or its principals, is a shareholder, member or partner. Such assignee may also
include additional shareholders, members, or members in the discretion of Purchaser. Except as
otherwise provided in the foregoing, any transfer to any third party shall require the written
approval of Seller, which shall not be unreasonably withheld.
(b) Governing Law. This Agreement is being delivered and is intended to be performed
in the State of Alabama and shall be construed and enforced in accordance with the laws of such
State.
(c) Binding Effect. All the terms of this Agreement shall be binding upon and inure
to the benefit of, and be enforceable by, the parties hereto and their respective heirs, executors,
administrators, successors, and assigns.
(d) Exhibits. The Exhibits attached to this Agreement are incorporated herein and
made a part hereof as though fully set out herein.
(e) Survival. All the terms and conditions of this Agreement not performed at Closing
shall survive the Closing hereunder notwithstanding the delivery and acceptance of the Deed.
(f) Construction. The section and subsection captions and headings herein are for
convenience only and shall not affect the construction of any of the terms and provisions of this
Agreement.
(g) Attorneys Fees. In the event of litigation, if either party receives a judgment,
settlement, or award in its favor (the Receiving Party) against the other party (the Paying
Party) regarding an action under this Agreement, the Paying Party will pay upon demand all of
13
the Receiving Partys costs, charges, and expenses, including reasonable attorneys fees and
expenses, associated with such legal action; provided, however, if, prior to commencement of a
trial, the Paying Party offered to pay an amount equal to or in excess of such judgment,
settlement, or award, then the Receiving Party shall not be entitled to any such costs, charges,
expenses, or attorneys fees associated with such legal action.Should either party employ an
attorney or attorneys to enforce any of the provisions of this Agreement, or to protect its
interest in any matter arising under this Agreement, or to specifically enforce or to recover the
Earnest Money for breach of this Agreement, the party prevailing shall be entitled to recover from
the other party all reasonable costs, charges and expenses, including attorneys fees, expended or
incurred in connection therewith, including fees and expenses incurred on appeal or in any
bankruptcy action.
(h) Entire Agreement. This Agreement sets forth the entire agreement of the parties
and it shall not be changed except by written instrument signed by Seller and Purchaser.
(i) Facsimile or Email Signatures. The parties agree that (i) this Agreement may be
transmitted between them by facsimile or email, (ii) that this Agreement may be executed by
facsimile signatures or email signatures in PDF format, (iii) that such facsimile or email
signatures shall have the effect of original signatures relative to this Agreement, and (iv) they
will circulate signature pages to be countersigned and attached within five (5) business days of
the date of this Agreement.
(j) Counterparts. This Agreement may be executed in one or more counterparts and
shall become effective when one or more counterparts have been signed by all of the parties, and
each counterpart shall be deemed an original but all counterparts shall constitute a single
instrument.
[Signatures appear on the following page]
14
IN WITNESS WHEREOF, the parties have executed this Agreement on the respective dates set out
below, effective as of the date first set forth above.
|
|
|
|
|
ATTEST:
|
SELLER:
BELK, INC.
|
|
/s/ L.T.
Moore |
By: |
/s/ William
L. Wilson |
|
|
|
Name: |
William L. Wilson |
|
|
|
Its: |
Executive Vice President |
|
|
Date of Execution: March 11, 2008 |
|
|
|
|
|
|
|
ATTEST:
|
PURCHASER:
BROOKWOOD PHARMACEUTICALS, INC.
|
|
/s/ John
C. Middleton |
By: |
/s/ Arthur
J. Tipton |
|
|
|
Name: |
Arthur J. Tipton |
|
|
|
Its: |
President |
|
|
Date of Execution: March 11, 2008 |
|
15
EXHIBIT A
(Description of Real Property)
A-1
EXHIBIT A-1
(Survey of Real Property)
A-2
Schedule 3(f)
(List of Licenses and Permits)
Schedule 3(f)
Schedule 3(g)
(List of Service Contracts)
Schedule 3(g)
exv31w1
EXHIBIT 31.1
CERTIFICATION PURSUANT TO SECTION 302
OF SARBANES-OXLEY ACT OF 2002
I, Bruce J Barclay, certify that:
1. I have reviewed this quarterly report on Form 10-Q of SurModics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d- 15(f)) for the registrant and we have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrants internal control over financial reporting; and
5. The registrants other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the audit
committee of the registrants board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrants internal control over financial reporting.
|
|
|
|
|
|
|
|
Dated: May 9, 2008 |
Signature: |
/s/ Bruce J Barclay
|
|
|
|
Bruce J Barclay |
|
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer) |
|
exv31w2
EXHIBIT 31.2
CERTIFICATION PURSUANT TO SECTION 302
OF SARBANES-OXLEY ACT OF 2002
I, Philip D. Ankeny, certify that:
1. I have reviewed this quarterly report on Form 10-Q of SurModics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d- 15(f)) for the registrant and we have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrants internal control over financial reporting; and
5. The registrants other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the audit
committee of the registrants board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrants internal control over financial reporting.
|
|
|
|
|
|
|
|
Dated: May 9, 2008 |
Signature: |
/s/ Philip D. Ankeny
|
|
|
|
Philip D. Ankeny |
|
|
|
Senior Vice President and Chief Financial Officer
(Principal Financial Officer) |
|
exv32w1
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of SurModics, Inc. (the Company) on Form 10-Q for
the quarter ended March 31, 2008, as filed with the Securities and Exchange Commission (the
Report), I, Bruce J Barclay, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of
the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
|
|
|
|
|
|
|
|
Dated: May 9, 2008 |
/s/ Bruce J Barclay
|
|
|
Bruce J Barclay |
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer) |
|
exv32w2
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of SurModics, Inc. (the Company) on Form 10-Q for
the quarter ended March 31, 2008, as filed with the Securities and Exchange Commission (the
Report), I, Philip D. Ankeny, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906
of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
|
|
|
|
|
|
|
|
Dated: May 9, 2008 |
/s/ Philip D. Ankeny
|
|
|
Philip D. Ankeny |
|
|
Senior Vice President and Chief Financial Officer
(Principal Financial Officer) |
|
|